With 15 years of experience in consumer healthcare and fast-moving consumer goods, Thomas will be responsible for supporting MAYOLY’s growth across Central and Eastern Europe and strengthening the Group’s presence in this strategic region. This appointment reflects MAYOLY’s ambition to accelerate its international development by relying on recognized talents and pursuing its mission: delivering innovative and accessible healthcare solutions for patients and healthcare professionals. Welcome to MAYOLY, Thomas, and best wishes for this new entrepreneurial journey!

At Mayoly, we remain committed to supporting the climate transition through greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi).

By 2030, we are committed to reducing our direct emissions (Scopes 1 and 2) by 50% compared with 2019, and our indirect emissions (Scope 3) by 55% per million euros of value added.

We are already making tangible progress. Thanks to our increased use of renewable electricity and the gradual electrification of our sites, we have reduced our Scope 1 and 2 emissions by 41% in fiscal year 2025, compared with 2019.

At the same time, our emissions remained stable in 2025 despite the continued growth of our business, demonstrating our ability to combine business growth with environmental responsibility.

Our next challenge is to accelerate emissions reductions across our value chain, including purchasing, transportation and other upstream and downstream activities. To achieve this, we are already working closely with our partners to develop increasingly sustainable solutions.

TOPICREM reaches a new milestone in its scientific commitment with the publication of its first study in the Journal of Cosmetic Dermatology (JCD), a leading international journal in dermo-cosmetics.

This publication highlights the results of a clinical study conducted on two flagship products: the Relipidizing Cleansing Oil and the DA PROTECT Emollient Balm, developed to meet the specific needs of atopic-prone skin.

Clinically proven results

The study underscores the benefits of daily use of these products, including:

· strengthening of the skin barrier
· improvement in hydration and comfort
· a significant contribution to quality of life and emotional well-being in patients with atopic dermatitis

These results confirm TOPICREM’s expertise in developing skincare that combines dermatological performance with sensorial appeal.

A commitment to patients

This publication reflects TOPICREM’s determination to rely on robust scientific data to support patients in their daily lives. It also demonstrates the teams’ dedication to designing innovative formulas aimed at sustainably improving the comfort of sensitive and atopic skin.

👉 View the full study: HERE